From Financial Modeling Prep: 2024-12-13 01:00:03

Bluebird bio, Inc. (NASDAQ: BLUE) is a biotech company specializing in gene therapies for genetic diseases, aiming to improve patient outcomes. To meet Nasdaq requirements, BLUE executed a 1-for-20 reverse stock split on December 13, 2024, stabilizing stock prices. With a market cap of $73.89 million, this move ensures future growth and investor trust.



Read more at Financial Modeling Prep:: bluebird bio, Inc. (NASDAQ: BLUE) Implements Rever…